PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
52.82%
R&D growth above 1.5x CRVO's 5.59%. Michael Burry would check for spending discipline.
-14.04%
G&A reduction while CRVO shows 37.03% growth. Joel Greenblatt would examine efficiency advantage.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
9.04%
Operating expenses growth less than half of CRVO's 251.41%. David Dodd would verify sustainability.
9.04%
Total costs growth 50-75% of CRVO's 15.98%. Bruce Berkowitz would examine efficiency.
104.89%
Interest expense change of 104.89% while CRVO maintains costs. Bruce Berkowitz would investigate control.
No Data
No Data available this quarter, please select a different quarter.
-9.04%
Both companies show EBITDA decline. Martin Whitman would check industry conditions.
No Data
No Data available this quarter, please select a different quarter.
-9.04%
Both companies show declining income. Martin Whitman would check industry conditions.
No Data
No Data available this quarter, please select a different quarter.
114.37%
Other expenses growth while CRVO reduces costs. John Neff would investigate differences.
48.96%
Pre-tax income growth while CRVO declines. John Neff would investigate advantages.
No Data
No Data available this quarter, please select a different quarter.
135.99%
Tax expense change of 135.99% while CRVO maintains burden. Bruce Berkowitz would investigate strategy.
48.96%
Net income growth while CRVO declines. John Neff would investigate advantages.
No Data
No Data available this quarter, please select a different quarter.
53.59%
EPS growth while CRVO declines. John Neff would investigate advantages.
51.99%
Diluted EPS growth while CRVO declines. John Neff would investigate advantages.
10.21%
Share count reduction below 50% of CRVO's 2.84%. Michael Burry would check for concerns.
6.42%
Diluted share reduction below 50% of CRVO's 2.84%. Michael Burry would check for concerns.